1. Introduction {#s0005}
===============

Osteogenesis imperfecta (OI) is a heterogeneous group of genetic disorders of the connective tissue that cause skeletal fragility, multiple fractures, and other extraskeletal manifestations. Most cases of OI are caused by heterozygous mutations in *COL1A1* or *COL1A2*, the genes encoding the two type I procollagen alpha chains, pro-alpha1 and pro-alpha2. Mutations in these genes result in quantitative and/or qualitative defects in type I collagen production by osteoblasts ([@bb0030]; [@bb0060]; Van [@bb0065]).

More recently, studies have discovered several genes responsible for OI inherited as an autosomal recessive trait ([@bb0005]; [@bb0010]; [@bb0050]; [@bb0025]). Among these genes, *LEPRE1* encodes prolyl 3-hydroxylase 1 (P3H1), which forms a molecular complex with cartilage associated protein (CRTAP) and cyclophilin B (CypB) encoded by *PPIB*, in the endoplasmic reticulum (ER) that is responsible for one step in collagen post-translational modification, the prolyl 3-hydroxylation of specific proline residues, specifically a1(I) Pro986. P3H1 provides the enzymatic activity of the complex and is the only component of the complex with a Lys-Asp-Glu-Leu (KDEL) ER-retrieval sequence at the carboxyl terminus ([@bb0060]). One *LEPRE1* mutation (c.1080 + 1G \> T) has a carrier frequency of about 1/240 in the African American population, most commonly resulting in a lethal form of OI when present in a homozygous state ([@bb0015]).

To date, more than 40 *LEPRE1* mutations have been described and the natural history of patients with a *LEPRE1* mutation is a severe or lethal presentation of the disease ([@bb0055]). Here we report the case of a five year old male with a moderate form of OI and compound heterozygous *LEPRE1* mutations (c.1080 + 1G \> T (paternal); c.1646 T \> G, p.Met549Arg (maternal)). Usually the c.1080 + 1G \> T mutation is severe or lethal when homozygous (Pepin, 2013). The mutation c.1646 T \> G is a novel missense mutation. The resulting substitution of methionine by arginine at position 549 occurs in the prolyl-hydroxylase domain of the protein. This case description serves to expand the clinical phenotyping of this recessive form of OI into the more moderate spectrum.

2. Case report {#s0010}
==============

The patient is a now 5 year old male with a moderate form of OI. He was the fourth pregnancy for his then 30 year old mother and the sixth pregnancy for his then 39 year old father.

There is no known family history of OI or any other bone dysplasia. There is no consanguinity. The patient\'s mother is of Scottish/Irish/British ancestry. Her height is 5′2″. She has no fracture history. The patient\'s father is of West African/Irish/Canadian/Indian ancestry. He has a history of nephritis, asthma, chronic obstructive pulmonary disease (COPD), and two transient ischemic attacks of the brain. His height is 5′8″. He has no fracture history.

The pregnancy was recognized at four to five weeks and prenatal care began at eight weeks of gestation. There were no maternal medical problems affecting the pregnancy. Prenatal vitamins were taken daily as well as ondansetron as needed for nausea. There was cigarette smoking during pregnancy (6--7 cigarettes daily). A single 12 week ultrasound did not detect any abnormalities. The amniotic fluid level was normal. Fetal movements were described as decreased. There were premature contractions beginning at 35 weeks of gestation. A decision was made to induce labor at 39 weeks gestation. Rupture of membranes was artificial. Labor was difficult and presentation was occiput anterior. Delivery was vaginal with vacuum assistance. The birth weight was 7 lb, 4 oz and the birth length was 18.5 in. He was discharged on day of life one and seen by his pediatrician on day of life two. He was noted to have a swollen right upper arm and decreased leg movements with frog legged posture. Referral to orthopedics was made and he was evaluated by a pediatric orthopedist on day of life 12. His parents reported that during this interval he was fussy and crying and likely in pain. A skeletal survey at that time demonstrated both sub-acute and chronic changes. Fractures with associated periosteal reactions and callus could be identified in the right humeral diaphysis, right clavicle, right distal femur, right proximal tibia, right distal fibula and left distal tibia. All of these appeared to be in the same stage of healing and are highly suggestive of perinatal fractures (See [Fig. 1](#f0005){ref-type="fig"}). In addition a skull fracture was noted and likely related to vacuum extraction. No vertebral body fractures were noted. Chronic changes of symmetric, bowed and undermodeled femurs were noted and suggestive of *in utero* fractures. Symmetric bulbous changes were also seen at the distal ends of the ribs bilaterally. Initial genetic testing from blood failed to demonstrate and mutations in *COL1A1* and *COL1A2*. Subsequent testing identified compound heterozygous changes in the *LEPRE1* gene (c.1080 + 1G \> T, c.1646 T \> G). No changes were identified in *CRTAP*, *PPIB*, *FKBP10*, *SERPINF1*, *PLOD2*, *SERPINH1*, *SP7 or ALPL* (Collagen Diagnostic Lab, University of Washington). The c.1080 + 1G \> T mutation is the common West African allele and is known to cause severe or lethal OI when homozygous ([@bb0055]). The c.1646 T \> G mutation is a novel missense mutation. The resulting substitution of methionine by arginine at position 549 occurs in the prolyl-hydroxylase domain of the protein. Follow-up testing from a skin biopsy and parental blood samples demonstrated paternal inheritance of the c.1080 + 1G \> T variant and maternal inheritance of the c.1646 T \> G variant. No differences were identified in the secretion or electrophoretic mobility of types I and III procollagens. The efficiency and conversion of procollagens to collagen were similar to control cells.Fig. 1Radiographic images. Lower extremities (panel A) and right humerus (panel B) at 12 days of age. Lower extremities at 1 year of age (panel C) and 4 years 6 months (panel D). Anterior posterior (AP) (panel E) and lateral (panel F) thoracolumbar spine. AP of right femur fracture at 4 years 7 months (panel G). AP (panel H) and lateral (panel I) images obtained 8 weeks postoperatively demonstrating Fassier-Duval rod placement and healing of the fracture and osteotomy. Lower extremities at 5 months postoperatively.Fig. 1

The patient was started on a pamidronate therapy at seven weeks of age at a dose of 9.0 mg/kg/year ([@bb0035]). An initial L1-L4 bone mineral density (BMD) was measured at 0.092 g/cm^2^ (Hologic Delphi). A *Z*-score could not be calculated due to the patient\'s age. Following two years and 17 cycles of treatment, the pamidronate dosing was reduced to 4.5 mg/kg/year due to improved BMD, a lack of fractures and pain. L1-L4 BMD at that point measured 0.383 g/cm^2^ (Hologic Discovery A). Again a *Z*-score could not be calculated, however this represented an interval increase of 316%. At three years of age, pamidronate therapy was discontinued due to distal femoral BMD *Z*-scores above the normal range (+2.7 on the left and + 2.8 of the right). L1-L4 BMD was 0.436 g/cm^2^ (Z-score-0.4) (Hologic Discovery A). At age 4.5 years, a DEXA scan continued to demonstrate elevated bone densities. At diagnosis and throughput his treatment his calcium, phosphorus and alkaline phosphatase levels have been normal. 25-hydroxy Vitamin D levels were supplemented into the normal range.

The patient\'s height has increased steadily with Z-scores consistently between −2 and −3. His weight is tracking at approximately the 25th percentile on the CDC grid for boys. Developmentally, he rolled at seven months, sat at nine months and walked at 14 months. The patient has appropriate hearing and vision. There is no evidence for dentinogenesis imperfecta or blue sclera.

On physical examination, there is anterolateral bowing of both femurs which improved with observation from the neonatal period until the age of 4.5 years ([Fig. 1](#f0005){ref-type="fig"}). Bilateral hip internal rotation is 30°, external rotation on the left 40°, and on the right 45°, bilateral hip flexion 110°, knee ROM 0--130°, popliteal angles 10° bilaterally. Bilateral foot dorsiflexion with the knees in full extension is 10° and bilateral foot dorsiflexion with knees in 90° of flexion is 20°. The left thigh foot angle is −10° and the right thigh foot angle is −5°. The patient has bilateral mild pes flexible planovalgus.

The post‑neonatal fracture history includes three fractures. At 18 months of age the patient was identified as having a right parietal calvarial fracture following an episode of altered consciousness. The fracture was an incidental imaging finding and remote from the acute episode. At four years and seven months of age, the patient fell at preschool and sustained a right femur fracture. The right femur fracture has been treated with an osteotomy and intramedullary Fassier-Duval rodding as demonstrated in [Fig. 1](#f0005){ref-type="fig"}. At 5 years 4 months, while playing outside, he fell and transversely fracture his left subtrochanteric femur. This was treated with an osteotomy and intramedullary Fassier-Duval rodding. No vertebral fractures have been noted.

3. Discussion {#s0015}
=============

We report, to our knowledge, the most moderate case of a patient with a OI due to compound heterozygous mutations in *LEPRE1*. Typically biallelic *LEPRE1* mutations are associated with a lethal to severe form of OI characterized by rhizomelic limb shortening, white sclerae, severe skeletal undermineralization, extreme growth deficiency and bulbous metaphyses ([@bb0015]; [@bb0020]; [@bb1000]). Our patient has white sclera, but is without rhizomelic limb shortening, severe undermineralization or extreme growth deficiency. His presentation in the perinatal period suggested multiple fractures associated with birth trauma, but also more chronic disease and *in utero* fractures with bilateral femoral bowing. Symmetric bulbous changes were also seen at the distal ends of the ribs bilaterally. No vertebral fractures have been noted. His is currently an ambulatory active child who has only two long bones fractures (right and left femurs) since the perinatal period. These fractures however, were significant and required bilateral rodding procedures.

He began pamidronate therapy using standard dosing ([@bb0035]) and has had a robust response with a more than 300% improvement although the measurements were made on different machines in different centers. There is little published on pamidronate therapy in OI, Type VIII. Willaert et al. described a patient whose BMD improved from a *Z*-score of −11.0 at 6 years old to −6.8 after treatment, but the treatment details were not documented. That individual had a severe thoracic kyphoscoliosis and had shortened, bowed and twisted limbs ([@bb0070]). Takagi also reported a child with Type VIII OI who began pamidronate therapy at 2 months of age and at 5, that child did not have severe deformity of the long bones and was able to walk with support ([@bb0060]). This robust response to pamidronate, may in part explain the few number of post-natal fractures.

The c.1080 + 1G \> T *LEPRE1* mutation is a well described pathogenic variant associated with OI type VIII. It has been termed the "West African allele," because it is seen in about half of the cases found in Ghana, Nigeria and among African-Americans patients ([@bb0015]). Our patient\'s father is of West African ancestry and is known to carry this allele. When this mutation is present in homozygosity or in conjunction with another nonsense mutation, and it almost uniformly leads to a very severe or lethal form of OI ([@bb0020]; [@bb0055]). Our patient\'s second allele, inherited from his mother, is a novel c.1646 T \> G mutation. The resulting substitution of methionine by arginine at position 549 occurs in the prolyl-hydroxylase domain of the protein and is expected to lead to a modified protein rather than an absence of protein. This amino acid appears to be highly conserved across primate and vertebrate species for which data is available in the UCSC Genome Browser (<http://genome.ucsc.edu>/) ([@bb0040]). This precise variant has not been identified in ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) nor the Exome Variant Server (<http://evs.gs.washington.edu/evs/>) ([@bb0045]). This type of missense mutation is not a common as a cause for patients with Type VIII OI. Pepin et al. analyzed *LEPRE1* alleles in 42 individuals with OI ([@bb0055]). Of the 46 distinct disease causing alleles identified 42 were either splice site, nonsense or frameshift mutations and predicted to lead to lack of P3H1 protein. Two of the remaining mutations likely did not affect mRNA stability but resulted in a protein that lacked the carboxyl-terminal rough ER (RER) localization signal (KDEL sequence). The consequence is functional haploinsufficiency through either rapid protein (P3H1) degradation or lack of P3H1 retention in the RER, or both ([@bb0055]). The remaining two mutations were missense, and each changed the last nucleotide of exon 8, a position that normally contributes to the function of the splice donor site. *In vitro* studies identified abnormal splice products, again leading to the absence of P3H1 ([@bb0055]). Other reports appear to document only a single additional patient with a missense mutation. That individual was a compound heterozygote with a splice site mutation and a missense mutation (c.1466 T \> C) ([@bb0075]). While severely affected, that individual is the oldest known surviving patient (See [Table 1](#t0005){ref-type="table"}).Table 1Clinical characteristics of long-term surviving patients with *LEPRE1* mutations.Table 1Patient 1 ([@bb0075])Patient 2 ([@bb0075])Patient 3 ([@bb0070])Patient 4 ([@bb0070])Our casePublished age (years + months)241717 + 785 + 6Clinical classificationSevereSevereSevere to lethalSevere to lethalModerateBlue scleraNoNoSlightYesNoHearing lossNoNoNoNANoDentinogenesis imperfectaNoNoNANoNoLimb deformitySevereSevereSevereSevereModeratePopcorn epiphysesNoNoYesYesNoShort statureYes, 110 cmYes, 130 cmNANAYes, 97 cm (−2.92 *Z*-score)Mutation typesAllele oneSplice siteSplice siteSplice siteSplice siteSplice siteAllele twoMissenseNonsenseNonsenseSplice siteMissense

The Type I procollagen molecules synthesized by cells from most individuals with mutations that significantly reduce the amount of CRTAP, P3H1, or CYPB are overmodified ([@bb0010]). This overmodification can be measured by reduced electrophoretic mobility of collagen polypeptides due to increased posttranslational hydroxylation and glycosylation of lysyl residues ([@bb0010]). Our patient\'s procollagen electrophoretic mobility studies failed to demonstrate this classic pattern. It is believed that in the absence of P3H1 or CRTAP, there is a delay in triple helix formation with secondary prolonged exposure of the procollagen chains to other hydroxylation steps ([@bb0010]; [@bb2000]). In an individual with mutations that resulted no P3H1 activity on one allele and the loss of the KDEL ER-retrieval sequence on the other, P3H1 activity is retained and *in vitro* functional studies demonstrated a higher level of appropriate prolyl 3-hydroxylation in the a1(I) Pro986 position and a milder clinical phenotype that is somewhat similar to our patient. Despite this, protein overmodification is present and can be measured as reduced electrophoretic mobility ([@bb0060]). This patient suggests that the ability to have more normal prolyl 3-hydroxylation in the a1(I) Pro986 position may be independent of overmodification of the procollagen chains. Although P3H1 protein arising from the KDEL allele is likely normal, it may only have a transient presence in ER ([@bb0060]).

Our patient\'s missense mutation does not clearly affect the KDEL sequence, but more likely affects 3-hydroxylation given its location in the prolyl-hydroxylase domain of the protein. One could therefore, hypothesize that prolonged ER exposure and overmodification of procollagen chains is not purely a result of diminished P3H1 activity, but time the procollagen spend in the ER. If this is true, the combination of mutations present in our patient, could diminish the ER times but just lower levels of prolyl 3-hydroxylation in the a1(I) Pro986 position without resulting in protein overmodification. As is pointed out by Pepin et al., the milder end of the clinical spectrum could be due to as yet unidentified missense mutations in *LEPRE1* ([@bb0055]). Protein studies were not available from the 24 year old patient with a similar type of compound heterozygous mutations as our patient, but this long term survivor is also milder than the classic phenotype ([@bb0075]). Clinical characteristics of this individual and other published long term survivors are described in [Table 1](#t0005){ref-type="table"}. Given our patient\'s overall good health and milder skeletal phenotype, this case description serves to expand the clinical phenotyping of this recessive form of OI into the more moderate spectrum.
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